{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:26:08Z","timestamp":1792697168211,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05921-7","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T01:02:25Z","timestamp":1723856545000},"page":"4613-4620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Rafael Amorim Belo","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Avezum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"de Oliveira Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio Cesar Carvalho Guimar\u00e3es","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bachour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"5921_CR1","doi-asserted-by":"crossref","unstructured":"Banerji V, Aw A, Robinson S, Doucette S, Christofides A, Sehn LH (2020). Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia. Current Oncology 27(6).","DOI":"10.3747\/co.27.6795"},{"key":"5921_CR2","doi-asserted-by":"crossref","unstructured":"Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al (2022). Management of cardiovascular complications of Bruton tyrosine kinase inhibitors. Br J Haematol 196(1).","DOI":"10.1111\/bjh.17788"},{"key":"5921_CR3","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al (2021). Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology 39(31).","DOI":"10.1200\/JCO.21.01210"},{"key":"5921_CR4","doi-asserted-by":"crossref","unstructured":"Seymour JF, Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, et al (2021). Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood 138(Supplement 1).","DOI":"10.1182\/blood-2021-146228"},{"key":"5921_CR5","doi-asserted-by":"crossref","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al (2018). Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol 4(12):1491\u20131500. doi: 10.1016\/j.jacep.2018.06.004.","DOI":"10.1016\/j.jacep.2018.06.004"},{"key":"5921_CR6","doi-asserted-by":"crossref","unstructured":"Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al (2020). Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. 142(25).","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"5921_CR7","doi-asserted-by":"crossref","unstructured":"Zimmerman SM, Peer CJ, Figg WD (2021). Ibrutinib\u2019s off-target mechanism: cause for dose optimization. Cancer Biol Ther 22(10\u201312).","DOI":"10.1080\/15384047.2021.1980313"},{"key":"5921_CR8","doi-asserted-by":"crossref","unstructured":"Thompson PA, L\u00e9vy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, et al (2016). Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3).","DOI":"10.1111\/bjh.14324"},{"key":"5921_CR9","doi-asserted-by":"crossref","unstructured":"Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al (2022). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 107(6).","DOI":"10.3324\/haematol.2021.278901"},{"key":"5921_CR10","doi-asserted-by":"crossref","unstructured":"Guha, A, Derbala, M, Zhao, Q. et al (2018). Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol 72 (6) 697\u2013698.","DOI":"10.1016\/j.jacc.2018.06.002"},{"key":"5921_CR11","doi-asserted-by":"crossref","unstructured":"Bhat SA, Gambril J, Azali L, et al (2022). Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 17; 140(20):2142\u20132145.","DOI":"10.1182\/blood.2022016953"},{"key":"5921_CR12","doi-asserted-by":"crossref","unstructured":"Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ (2021). Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res 128(12).","DOI":"10.1161\/CIRCRESAHA.121.318259"},{"key":"5921_CR13","doi-asserted-by":"crossref","unstructured":"Htut TW, Han MM, Thein KZ. Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials (2022). J Immunother Precis Oncol 5(2).","DOI":"10.36401\/JIPO-21-12"},{"key":"5921_CR14","doi-asserted-by":"crossref","unstructured":"Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, et al (2022). Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol 15(1).","DOI":"10.1186\/s13045-022-01302-7"},{"key":"5921_CR15","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan AAA, Furman RR, et al (2021). Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology 39(31):3441\u20133452.","DOI":"10.1200\/JCO.21.01210"},{"key":"5921_CR16","doi-asserted-by":"crossref","unstructured":"Lipsky AH, Farooqui MZH, Tian X, Martyr S, Cullinane AM, Nghiem K, et al (2015). Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 100(12).","DOI":"10.3324\/haematol.2015.126672"},{"key":"5921_CR17","doi-asserted-by":"crossref","unstructured":"Wang J, Zhao A, Zhou H, Zhu J, Niu T (2020). Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 11: 580622.","DOI":"10.3389\/fphar.2020.580622"},{"key":"5921_CR18","doi-asserted-by":"crossref","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov A V., DeLoughery TG (2017). Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 15(5):835\u2013847.","DOI":"10.1111\/jth.13651"},{"key":"5921_CR19","doi-asserted-by":"crossref","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan AA, Furman RR, et al (2023). Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR. Blood 142(8):687\u2013699.","DOI":"10.1182\/blood.2022018818"},{"key":"5921_CR20","doi-asserted-by":"crossref","unstructured":"Vassilopoulos S, Shehadeh F, Kalligeros M, Tran QL, Schiffman F, Mylonakis E (2022). Targeted therapies in CLL\/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. Front Pharmacol 13:989830.","DOI":"10.3389\/fphar.2022.989830"},{"key":"5921_CR21","doi-asserted-by":"crossref","unstructured":"Hilal T, Hillegass WB, Gonzalez-Velez M, Leis JF, Rosenthal AC (2020). Adverse Events in Clinical Trials of Ibrutinib and Acalabrutinib for B-Cell Lymphoproliferative Disorders: A Systematic Review and Network Meta-Analysis. Blood 136(Supplement 1).","DOI":"10.1182\/blood-2020-137062"},{"key":"5921_CR22","doi-asserted-by":"crossref","unstructured":"Sanchez JM, Jolly SE, Dewland TA, et al (2019). Incident atrial fibrillation among American Indians in California.Circulation.; 140: 1605\u20131606.","DOI":"10.1161\/CIRCULATIONAHA.119.042882"},{"key":"5921_CR23","doi-asserted-by":"crossref","unstructured":"Martinez C, Katholing A, Wallenhorst C, Granziera S, Cohen AT, Freedman SB (2015). Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. Heart 101: 1748\u20131754.","DOI":"10.1136\/heartjnl-2015-307808"},{"key":"5921_CR24","doi-asserted-by":"crossref","unstructured":"Rudd KE, Johnson SC, Agesa KM, et al (2020). Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet 395(10219):200\u2013211. doi: 10.1016\/S0140-6736(19)32989-7.","DOI":"10.1016\/S0140-6736(19)32989-7"},{"key":"5921_CR25","doi-asserted-by":"crossref","unstructured":"Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S., et al (2023). Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv 7(16):4291\u20134301. doi: https:\/\/doi.org\/10.1182\/bloodadvances.2023009739","DOI":"10.1182\/bloodadvances.2023009739"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05921-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T04:28:02Z","timestamp":1730694482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05921-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5921"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05921-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4335215\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rafael A. Belo Nunes has no conflict of interest. \u00c1lvaro Avezum has no conflict of interest. Mariana de O. Marques and Phillip Bachour have received speaking honoraria from Janssen.Otavio Cesar C. G. Baiocchi has received speaking honoraria from Janssen and AstraZeneca. No company played any role in the development, review, or approval of the manuscript nor the decisions regarding submitting this manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}